Ascendis Pharma A/S
TransCon CNP
pediatric achondroplasia
Resolved
98days ago
Approval decision · ~ Mar 31, 2026 estimated
What's at stake
A final FDA approval decision on TransCon CNP for pediatric achondroplasia is expected ~ Mar 31, 2026.
Primary source
· SEC 6-K
verified 15h ago
“regulatory decision on potential use in pediatric achondroplasia anticipated in the fourth quarter of 2026.”